SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-85204"
 

Search: onr:"swepub:oai:DiVA.org:oru-85204" > Influenza vaccinati...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Joona, Therse BjörkinDepartment of Oncology, Västerås Central Hospital, Västerås, Sweden,Västerås Hosp, Dept Oncol, Västerås, Sweden. (author)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-08-01
  • Springer,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-85204
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-85204URI
  • https://doi.org/10.1007/s10549-020-05815-yDOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-439244URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agency:Örebro University
  • Background: Despite the current recommendation for influenza vaccination in cancer patients with active oncological therapy, limited data are available on the efficacy of vaccination in cancer patients receiving targeted therapies. We aimed to investigate the immunogenicity and tolerability of influenza vaccination in breast cancer patients treated with trastuzumab in adjuvant setting.Methods: A prospective open-label multicenter study was performed including patients with breast cancer during trastuzumab treatment in adjuvant setting and healthy controls. Blood samples were taken before, 4 weeks after, and 12 weeks after a single dose of trivalent influenza vaccine containing inactivated A/California/7/2009 (H1N1) pdm09, A/Hongkong4801/2014 (H3N2), and B/Brisbane/60/2008. Levels of serum antibody titers to hemagglutinin for H1N1 and influenza B strains were measured.Results: Twenty breast cancer patients and 37 controls were included in the study. No difference in seroprotection rate between trastuzumab-treated patients and controls was observed for either H1N1 (100% in both groups) or B strain (78.9% vs. 89.2%,pvalue = 0.423). A statistically significant increase in geometric mean titers from baseline was seen in both groups and was evident both 4 weeks and 12 weeks after vaccination. Adverse events in the trastuzumab-treated group were uncommon and mild with only one serious adverse event not related to vaccination.Conclusion: Breast cancer patients treated with trastuzumab in adjuvant setting seem to benefit from influenza vaccination in terms of immunogenicity without increasing the risk for adverse events. The current data support the recommendation to offer influenza vaccination in breast cancer patients treated with this type of targeted therapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Digkas, EvangelosDepartment of Oncology, Mälarsjukhuset, Eskilstuna, Sweden,Malarsjukhuset, Dept Oncol, Eskilstuna, Sweden. (author)
  • Wennstig, Anna-KarinDepartment of Oncology, Sundsvall Hospital, Sundsvall, Sweden,Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden. (author)
  • Nyström, Karin,1978-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology,Örebro Univ, Fac Med & Hlth, Dept Oncol, S-70182 Örebro, SE, Sweden.(Swepub:oru)kinm (author)
  • Nearchou, AndreasDepartment of Oncology, Mälarsjukhuset, Eskilstuna, Sweden,Malarsjukhuset, Dept Oncol, Eskilstuna, Sweden. (author)
  • Nilsson, CeciliaDepartment of Oncology, Västerås Central Hospital, Västerås, Sweden,Västerås Hosp, Dept Oncol, Västerås, Sweden. (author)
  • Pauksen, KarlisUppsala universitet,Infektionsmedicin(Swepub:uu)karlpauk (author)
  • Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology,Örebro Univ, Fac Med & Hlth, Dept Oncol, S-70182 Örebro, SE, Sweden.(Swepub:oru)asvs (author)
  • Department of Oncology, Västerås Central Hospital, Västerås, SwedenVästerås Hosp, Dept Oncol, Västerås, Sweden. (creator_code:org_t)

Related titles

  • In:Breast Cancer Research and Treatment: Springer184:1, s. 45-520167-68061573-7217

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view